A Review of Affective (Mood) Disorders - PowerPoint PPT Presentation

1 / 61
About This Presentation
Title:

A Review of Affective (Mood) Disorders

Description:

A Review of Affective Mood Disorders – PowerPoint PPT presentation

Number of Views:354
Avg rating:3.0/5.0
Slides: 62
Provided by: msm962
Category:

less

Transcript and Presenter's Notes

Title: A Review of Affective (Mood) Disorders


1
A Review of Affective (Mood) Disorders
  • Ashley Owen, Ph.D.
  • Department of Family
  • and Preventive Medicine

2
Major Depressive Episode - Assessment
  • A. Five or more of the following symptoms have
    been present during the same 2-week period and
    represent a change from previous functioning.
  • 1. Depressed mood most of the day
  • 2. Markedly diminished interest or pleasure in
    activities most of the day, nearly every day.
  • 3. Significant weight loss when not dieting or
    weight gain or decrease or increase in
  • appetite nearly every day.

3
Major Depressive Episode - Assessment (contd)
  • 4. Insomnia or hypersomnia nearly every day.
  • 5. Psychomotor agitation or retardation.
  • 6. Fatigue or loss of energy nearly every day.
  • 7. Feelings of worthlessness or excessive guilt.
  • 8. Diminished ability to think or concentrate.
  • 9. Recurrent thoughts of death.

4
SIGECAPS Assessment (Neurovegetative Sx)
  • S- Is your sleep disturbed?
  • I- Have you noted a loss of libido or interest in
    your usual activities?
  • G-Are you feeling guilty or having
    self-deprecatory thoughts?
  • E-Have you noticed a decrease in your energy
    level?
  • C-Have you been having trouble concentrating?
  • A-Have you experienced changes in your appetite
    or weight?
  • P-Have you been physically slowed down or sped
    up? (psychomotor abnormalities)
  • S- Have you had thoughts of hurting yourself,
    feelings of hopelessness, preoccupation with
    issues related to death, or suicide?

5
Depression Screening - Assessment
  • Ask
  • 1.During the past month, have you been often
    bothered by little interest or pleasure in doing
    things?
  • 2.During the past month, have you been feeling
    down, depressed, or hopeless?
  • If yes to either further assessment
  • SIGECAPS or administer a measure

6
Depression Screening - Assessment
  • Measures
  • Beck Depression Inventory (BDI)
  • Edinburgh Postnatal Depression Scale (EPDS)
  • Geriatric Depression Scale (GDS)
  • Pediatric Symptom Checklist (PSC)
  • ALWAYS PERSONALLY REVIEW THE SUICIDE
  • ITEM AND DISCUSS WITH YOUR PATIENT!

7
Major Depressive Disorder
  • A. Presence of a Major Depressive episode
  • (single episode recurrent)
  • B. Not better accounted for by Schizoaffective
    Disorder
  • C. Never been a Manic Episode
  • Some patients become preoccupied with somatic
  • complaints such as bowel or bowel dysfunction.

8
Specifier HighlightsWith Psychotic Features
  • Important to assess!
  • Additional features of hallucinations (auditory
    or visual), delusions, bizarre bx, or
    disorganized thinking.

9
Specifier Highlights With Postpartum onset
  • Onset within 4 weeks of postpartum though
    studies suggest an extension of process that
    begins during pregnancy
  • affects 12-15 of women with good
    support/excited about being pregnant
  • - Affects 20-25 of women who are
    single/young/family disocord/no support
  • Baby blues (70) vs Postpartum Depression
    (10-15)
  • - decreased participation in prenatal
  • care and care following delivery
    (delayed social development)
  • - fetal exposure to stress hormones
  • - negative maternal outcomes
  • - increased risk of divorce (2-3)

10
Specifier HighlightsWith Atypical Features
  • 1. Mood reactivity (mood brightens in response to
    actual or potential positive events)
  • 2. Two or more of the following criteria
  • Significant weight gain or increase in appetite
  • Hypersomnia
  • Leaden paralysis (heavy, laden feelings in arms
  • or legs)
  • Long-standing pattern of interpersonal rejection
    sensitivity that results in significant social or
    occupational impairment

11
Specifier Highlights With Seasonal Pattern
  • Hx of temporal relationship between season and
    onset of major depressive episode
  • Typically notice onset
  • in fall or winter with
  • progressing resolution
  • of sxs in spring
  • or summer
  • Depressive sxs generally
  • atypical hypersomnia,
  • hyperphagia, and weight gain

12
Major Depressive Disorder -course and prevalence
  • stressor ? mediators ? reduced depression
  • (ex. social support, sense of control)
  • Life stressors ? Normal depressogenic reaction
  • Multiple major life stressors ? Multiple
    depressogenic reactions
  • - cognitions this is my life
  • extended periods of neurons being damaged by
    stress/depression
  • ? depressions cycle on their own rhythm in
    absence of stressors
  • ? increased risk of depression for the rest of
    the patients life without intervention

13
Major Depressive Disorder -course and prevalence
(contd.)
  • Evidence of biological effects of depression
  • Glucocorticoids (highly elevated) damage
    nervous system
  • - hippocampuses atrophy (poor synaptic
    activity disrupting neuronal connections
    neuronal atrophy)
  • - exercise/psychotropics/psychotherapy (or
    both) may impede this process and even
    initiate neurogenesis
  • Similar in anxiety amygdala (arousal, fear
    conditioning) networks strengthened
  • more connections,
  • more resilient pathways
  • Depression is a biological disorder that is very
    sensitive to the environment

14
Major Depressive Disorder -course and prevalence
(contd.)
Lifetime prevalence in women 1 in 4
(highest in gt44)
men 1 in 8 Age of onset often in mid-20s
(possibly earlier and undetected) 2/3 complete
remission of sxs, 1/3 partial remission and
increased likelihood of future episodes Single
episode 50 have a future episode 70 of those
who have 2 episodes have a third 90 of those
with 3 episodes have a fourth Possible
increased fx of episodes with age - relapse
prevention.
15
Dysthymic Disorder
  • Depressed mood for most of the day, for at least
    two years.
  • Presence, while depressed, of two or more of the
    following
  • Poor appetite or overeating
  • Insomnia or hypersomnia
  • Low energy or fatigue
  • Low self-esteem
  • Poor concentration or difficulty making decisions
  • Feelings of hopelessness

16
Dysthymic Disorder (contd.)
  • Sxs are less severe than those of MDD and
    neurovegetative sxs are fewer.
  • Common clinical feature generalized anhedonia
    or anergia
  • Also, social withdrawal, feelings of guilt or
    inadequacy, poor work or academic performance
  • Can be frustrating to treat because of chronic
    dysphoria, self-pity, and seemingly irrational
    patterns of negative thinking things always go
    wrong for me negative filter

17
Adjustment Disorder
  • Develops within 3 months of a significant life
    stressor
  • Symptoms are clinically significant as evidenced
    by either
  • marked distress in excess of what would be
    expected given the nature of the stressor
  • Or
  • Significant impairment in social or occupational
    functioning

18
Adjustment Disorder (contd.)
  • Symptoms dont represent Bereavement.
  • Presentation typically depressed mood, anxiety,
    helplessness, and worthlessness. Thoughts often
    predominated by activities that precipitated the
    event.
  • If criteria are met for MDD, this diagnosis
    supersedes Adjustment Disorder
  • Or when condition represents an exacerbation of a
    preexisting psych disorder
  • Remember to evaluate criteria regardless of event
    because evaluating need for intervention could be
    essential to patient in need of treatment.

19
Manic Episode
  • A distinct period of abnormally and persistently
    elevated, expansive, or irritable mood, lasting
    at least one week.

20
Manic Episode, contd.
  • During the period of mood disturbance, at least
    three of the following symptoms have persisted
    (four if only irritable)
  • Inflated self-esteem or grandiosity
  • Decreased need for sleep
  • Flight of ideas or subjective experience that
    thoughts are racing
  • More talkative than usual
  • Distractibility
  • Increase in goal directed activity
  • Excessive involvement in pleasurable activities

21
Bipolar Disorder, Type 1
  • Essential feature is occurrence of one or more
    Manic Episodes or Mixed Episodes (both Depressive
    and Manic episodes within 1-week period).
  • Often individuals have also
  • had one or more
  • Major Depressive Episodes
  • Episodes of Substance-Induced
  • Mood Disorder or of Mood Disorder
  • Due to a General Medical Condition
  • do not count toward a diagnosis of
  • Bipolar I Disorder.

22
Bipolar Disorder-Type II
  • Essential feature - occurrence of
  • one or more Major Depressive Episodes and at
    least one Hypomanic Episode
  • (not euthymia that follows remission of a
    Depressive Episode).
  • Episodes of Substance-Induced Mood Disorder or
    of Mood Disorder Due to a General Medical
    Condition do not count toward this diagnosis
  • (sxs consistent with manic sxs, but only have
    to last 4 days)

23
Cyclothymic Disorder
  • The presence of numerous periods with hypomanic
    symptoms
  • Numerous periods with depressive symptoms that do
    not meet criteria for a major depressive episode
    lasting for at least 2 years.
  • No major depressive episode, manic episode, or
    mixed episode.

24
Differential Diagnosis
  • Lyme disease
  • Fibromyalgia
  • Chronic Fatigue Syndrome
  • Rheumatoid disease
  • Endocrinopathies
  • Intimate Partner Violence
  • Other Psychiatric Disorders

25
Suicidality
  • About 15 of depressed patients take their life
  • Assess for
  • Thoughts (ideas, wishes, motives)
  • Intent (degree to which pt intends to act on
    those thoughts) - 1013
  • Plans (for self-harm)
  • Assess and document suicidality in all patients
    who report depressed mood, hopelessness,
    helplessness, or suffering
  • asking does not put ideas into their heads
  • Do you ever feel so badly that you would prefer
    not to go on living?

26
Psychotherapy Treatment
  • Psychodynamic approach
  • Cognitive-Behavioral approach
  • Interpersonal approach
  • Psychoanalytic therapy
  • Family therapy

27
Drug Classes
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Atypical Antidepressants
  • Tricyclic antidepressants (TCAs)
  • Others (MAOIs-monoamine
  • oxidase inhibitors, ECT, Bright Light)

28
General Information
  • Antidepressants show similar efficacy.
  • Seventy percent of patients will respond after
    4-6 weeks of therapy.
  • Approximately 7000 deaths per year from Tricyclic
    Antidepressant overdose.

29
SSRIs Class Side Effects
  • Nausea, diarrhea
  • decreased libido (especially in women)
  • Decreased appetite (especially Prozac)
  • Headache
  • Delayed orgasm

30
SSRIs Class Side Effects
  • If activation/ Insomnia (15)
  • ----gt take in morning.
  • If sedation(15)
  • ----gt take at bedtime.
  • Reduce GI side effects by taking medication with
    meals.
  • Dont use SSRIs in combination with MAOIs. Must
    wean SSRI before starting MAOI.
  • Lowest potential for toxicity from an overdose

31
SSRIs Prozac/fluoxetine
  • Long half-life
  • Reduced risk of SSRI Discontinuation Syndrome
  • Dose range is 10 - 80 mg/day

32
SSRIs Prozac/fluoxetine
  • Prozac has several interesting features
  • Tends to be activating (stimulation/restlessness).
    Consider another antidepressant for angry,
    irritable, depressed patients.
  • Weight loss a more dominant
  • side effect than weight gain.
  • Secondary to its effect on delayed ejaculation,
    it may be useful in treating premature
    ejaculation.

33
SSRIs Zoloft/sertraline
  • Shown efficacy for
  • Depression
  • Obsessive compulsive disorder (OCD)
  • Panic Disorder
  • Posttraumatic stress disorder (PTSD)
  • Dose range is 50-200 mg/day start at 25mg first
    week
  • Stimulating/GI and sexual side effects

34
SSRIs Paxil/paroxetine
  • Possibly more sedating than activating, but
    fairly neutral.
  • Efficacy shown in studies for
  • - major depressive disorder (MDD)
  • - obsessive compulsive disorder (OCD)
  • - panic disorder (PD)
  • Decreases seizure threshold
  • Dose range is 10-50 mg/day

35
SSRIs Celexa/citalopram
  • Side effect profile similar to other SSRIs
    though stimulation/restlessness may be less than
    other SSRIs
  • Dose range is 20-80 mg/day
  • LEXAPRO - derived by isolating the Celexa
    (citalopram HBr) molecule improved efficacy and
    side effects
  • Dose range is 10-20 mg/day

36
SSRIs Serotonin Syndrome
  • A syndrome involving

- Mental status changes
- High fever
- Muscular rigidity
- If not treated, potential coma and death
- Occurs in setting of multiple drugs which block
serotonin metabolism
37
SSRIs SSRI Discontinuation Syndrome
  • Flu-like (fatigue, myalgia, loose stools, and
    nausea)
  • Lightheadedness/dizziness
  • Uneasiness/restlessness
  • Sleep and sensory disturbance
  • Headache

38
Atypical Antidepressants
  • Desyrel/trazodone
  • Major side effect of note are sedation (most
    sedating of antidepressants), GI, and priapism
  • Starting dose is 50mg bid max dose 400mg
  • Most commonly used as a sedative in patients who
    may be depressed.

39
Atypical Antidepressants
  • Serzone/nefazodone - similar to trazodone
  • However, priapism not a side effect. Consider
    choosing this in men over trazodone.
  • Potential hepatic consequences requires hepatic
    monitoring
  • Should not be taken with antihistamines
  • Does not have sexual dysfunction as a common side
    effect, as do the SSRIs.
  • Major side effect is somnolence, though not as
    sedating as trazodone.
  • Starting dose 100mg bid.
  • May give up to 300-600 mg divided bid.

40
Atypical Antidepressants
  • Effexor/venlafaxine and Effexor XR
  • Shown efficacy in
  • depression,
  • generalized anxiety disorder (GAD)
  • social anxiety disorder
  • GI and sexual side effects
  • less sedation than many atypicals
  • Starting dosage is 37.5mg bid
  • maximum total daily dose is 375mg.

41
Atypical Antidepressants
  • Mirtazapine/Remeron
  • Dose range is 15-30mg qHS (bedtime) max dose
    45mg, secondary to sedation.
  • Side Effects
  • Somnolence in 50 of patients.
  • No increase in sexual dysfunction.
  • Agranulocytosis (low white cell count) in 11000
    (actually same statistic as other
    antidepressants, but noted on most side effect
    profiles).
  • Increased appetite and weight gain
  • can use in depressed patients
  • who are malnourished

42
Atypical Antidepressants
  • Wellbutrin/bupropion-Zyban (smoking cessation)
  • Is an activating antidepressant - makes people
    energetic vs sleepy.
  • Can also cause insomnia ----gt take in the morning
  • Contraindicated in patients with seizure disorder
    or eating disorder
  • Starting dose 100mg - dont give greater than
    200mg in one dose or greater than 450mg per day
  • Zyban 150mg 1st 3 days then 150am and
    150pm-8hrs apart
  • Some GI side effects
  • Inducing mania in bipolar less common
  • than other antidepressants
  • Not associated with weight gain
  • or disturbance in sexual fx

43
Atypical Antidepressants
  • Cymbalta/duloxetine
  • 20-30 mg BID depression
  • Diabetic peripheral neuropathic pain and
    depression-related pain sxs in elderly 60 mg
    once/day
  • Side Effects
  • -associated with slight increases in blood
    pressure
  • -not indicated for patients with
  • renal impairment
  • hepatic insufficiency/substantial alcohol
    use

44
Tricyclic Antidepressants
  • Elavil/amitriptyline
  • Tofranil/imipramine
  • Sinequan/doxepin
  • Pamelor/nortriptyline
  • Norpramin/desipramine

45
TCAs - Complex Side Effect and Drug Interaction
Potential
  • Anticholinergic - dry mouth, blurred vision,
    constipation, urinary retention, increased pulse
    monitor use of other anticholinergic
    treatments.
  • Cardiotoxicity - (contraindicated in pts w/hx of
    coronary event and recommended to obtain EKG
    prior to initiation)
  • Greatest risk of inducing mania in bipolar
  • Only class of antidepressants in which you can
    draw blood levels to document use
  • If prescribing in suicidal patient, no more than
    a 1-week supply should be dispensed at a time.

46
MAOIs
  • Nardil/phenelzine, Parnate/tranylcypromine
  • Major side effect is hypertensive crisis
  • Must be on a tyramine free diet (fermented
    cheese, yogurt, caffeine, chocolate, beer, and
    red wine)
  • At least two week washout before changing from
    SSRI to an MAOI or MAOI to SSRI
  • Drug and dietary interactions
  • complex rarely needed in
  • primary care

47
Others
  • Electroconvulsive therapy
  • Severe depression/
  • schizophrenia/bipolar
  • (induce seizures)
  • Retrograde amnesia
  • Can improve neuronal activity
  • and initiate neurogenesis
  • 50-80 of patients relapse within 6 -9 months
    (lithium and nortriptyline combo significantly
    reduces risk)
  • Bright Light used in seasonal affective disorder
  • Alaska, Canada, in the winter

48
When do you refer a patient to a psychiatrist?
  • Severe/recurrent depression
  • Suicidal patient
  • Depression with psychotic features (delusions,
    hallucinations, loss of contact with
    reality)
  • Bipolar disorder (Manic depression)
  • Monitor with frequent visits until consistently
    under referring doctors care

49
Special Cases
  • Pregnancy/Lactation
  • Consider SSRIs or buproprion (category B)
  • Weigh exposure risk
  • tx vs consequences of depression
  • Elderly
  • Consider SSRIs - beneficial side effect profile.
  • E.g., no orthostatic hypotension, no
    urinary retention in men. Start at low doses.


50
.
  • Discuss side effects and determine whats
    acceptable to patient.
  • Typically, no recipe determined a priori to be
    best for a patient an interactive process.
  • The secret of patient care is caring for the
    patient, making sure, once that initial treatment
    is chosen, that it is an interactive tailored
    process over time.
  • Patient will not respond if he or she stops the
    medication prematurely communication is key.

51
(No Transcript)
52
(No Transcript)
53
(No Transcript)
54
Review Questions ?
  • 1 You prefer to prescribe an antidepressant with
    the lowest potential for toxicity from an
    overdose. You should select
  • Tricyclic antidepressants
  • Monoamine oxidase inhibitors
  • Selective serotonin reuptake inhibitors
  • None of the above


55
Review Questions ?
  • 2. Which of the following antidepressants
    requires hepatic monitoring?
  • Trazodone/Desyrel
  • Nefazodone/Serzone
  • Bupropion/Wellbutrin
  • Paroxetine/Paxil


56
Review Questions ?
  • 3. There is an increased risk of developing
    serotonin syndrome if patients take a selective
    serotonin reuptake inhibitor along with
  • A. St. Johns wort
  • B. Nortriptyline/Pamelor
  • C. Bupropion/Wellbutrin
  • D. Kava Kava


57
Review Questions ?
  • 4. You are aware that a patient has been treated
    for depression with paroxetine. The patient
    presents with myalgias, disequilibrimum, and
    flu-like syndrome, and increased agitation. You
    should
  • Discontinue the paroxetine.
  • Double the paroxetine dose.
  • Switch the patient to venlafaxine
  • Determine whether patient has cut back or
    discontinued paroxetine.


58
Review Questions ?
  • 5. You believe a depressed patient would benefit
    from some sedation for sleep. Which of the
    following antidepressants is the most sedating?
  • A. Trazadone/Desyrel
  • B. Fluoxetine/Prozac
  • C. Bupropion/Wellbutrin
  • D. Nefazodone/Serzone


59
Review Questions ?
  • 6. Antidepressant medications may precipitate a
    manic or hypomanic episode in a patient with
    bipolar disorder. This is least likely to occur
    with
  • A. Amitriptylin/Elavil
  • B. Desipramine/Norpramin
  • C. Bupropion/Wellbutrin
  • D. Fluoxetine/Prozac
  • E. Paroxetine/Paxil


60
Review Questions ?
  • 7. Whats FLUSH?


61
Review Questions ?
  • 8. Whats SIGECAPS?

Write a Comment
User Comments (0)
About PowerShow.com